Abstract
Our earlier studies reported a unique potentiated combination (TriCurin) of curcumin (C) with two other polyphenols. The TriCurin-associated C displays an IC50 in the low micromolar range for cultured HPV+ TC-1 cells. In contrast, because of rapid degradation in vivo, the TriCurin-associated C reaches only low nano-molar concentrations in the plasma, which are sub-lethal to tumor cells. Yet, injected TriCurin causes a dramatic suppression of tumors in TC-1 cell-implanted mice (TC-1 mice) and xenografts of Head and Neck Squamous Cell Carcinoma (HNSCC) cells in nude/nude mice. Here, we use the TC-1 mice to test our hypothesis that a major part of the anti-tumor activity of TriCurin is evoked by innate and adaptive immune responses. TriCurin injection repolarized arginase1high (ARG1high), IL10high, inducible nitric oxide synthaselow (iNOSlow), IL12low M2-type tumor-associated macrophages (TAM) into ARG1low, IL10low, iNOShigh, and IL12high M1-type TAM in HPV+ tumors. The M1 TAM displayed sharply suppressed STAT3 and induced STAT1 and NF-kB(p65). STAT1 and NF-kB(p65) function synergistically to induce iNOS and IL12 transcription. Neutralizing IL12 signaling with an IL12 antibody abrogated TriCurin-induced intra-tumor entry of activated natural killer (NK) cells and Cytotoxic T lymphocytes (CTL), thereby confirming that IL12 triggers recruitment of NK cells and CTL. These activated NK cells and CTL join the M1 TAM to elicit apoptosis of the E6+ tumor cells. Corroboratively, neutralizing IL12 signaling partially reversed this TriCurin-mediated apoptosis. Thus, injected TriCurin elicits an M2→M1 switch in TAM, accompanied by IL12-dependent intra-tumor recruitment of NK cells and CTL and elimination of cancer cells.
Similar content being viewed by others
Abbreviations
- ARG1:
-
Arginase-1
- C:
-
Curcumin
- CD8:
-
Cluster of differentiation 8 protein
- CD8α:
-
Cluster of differentiation 8 alpha
- CTL:
-
Cytotoxic T lymphocytes
- CUNY:
-
City University of New York
- E:
-
Epicatechin gallate
- E6 16/18:
-
Early 6 protein 16/18
- E7:
-
Early 7 protein
- HaRas:
-
Harvey ras protein
- HCl:
-
Hydrochloric acid
- HNSCC:
-
Head and neck squamous cell carcinoma
- HPV:
-
Human papillomavirus
- IACUC:
-
Institutional Animal Care and Use Committee
- Iba1:
-
Ionized calcium-binding adapter molecule 1
- IF:
-
Integrated fluorescence
- IFNγ:
-
Interferon gamma
- IgG:
-
Immunoglobin G
- IL10:
-
Interleukin-10
- IL12:
-
Interleukin-12
- iNOS:
-
Inducible nitric oxide synthase
- LEEP:
-
Loop electrosurgical excision procedure
- LR:
-
Lower right
- NCr:
-
Athymic nude mice
- NKp46:
-
Natural killer cell p-46-related protein
- NOS2:
-
Nitric oxide synthase 2
- PFA:
-
Paraformaldehyde
- P-NF-kB:
-
Phospho-NF-kB
- P-p65:
-
Phospho-p65
- P-ser:
-
Phosphor-serine
- P-STAT1/3:
-
Phospho-STAT1/3
- P-Tyr:
-
Phospho-tyrosine
- R:
-
Resveratrol
- S.E.:
-
Standard error
- SEM:
-
Standard error of the mean
- SSC:
-
Saline-sodium citrate
- TAM:
-
Tumor-associated macrophage
- TriCur + IL12Ab:
-
‘IL12 antibody infusion followed by TriCurin treatment’ group
- UL:
-
Upper left
- UMSCC47:
-
University of Michigan-squamous cell carcinoma-47
- UR:
-
Upper right
- w/v:
-
Weight/volume
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics CA. Cancer J Clin 61:69–90
Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150. https://doi.org/10.1200/jco.2005.05.2308
Fowler RS (2000) Vulvar vestibulitis: response to hypocontactant vulvar therapy. J Low Genit Tract Dis 4:200–203
Stanley M (2010) Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol 118:2–7. https://doi.org/10.1016/j.ygyno.2010.04.002
Leemans CR, Braakhuis BJM, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9–22. https://doi.org/10.1038/nrc2982
Mirghani H, Amen F, Blanchard P, Moreau F, Guigay J, Hartl DM, Lacau St Guily J (2015) Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives. Int J Cancer 136:1494–1503. https://doi.org/10.1002/ijc.28847
Piao L, Mukherjee S, Chang Q et al (2017) TriCurin, a novel formulation of curcumin, epicatechin gallate, and resveratrol, inhibits the tumorigenicity of human papillomavirus-positive head and neck squamous cell carcinoma. Oncotarget 8:60025–60035. https://doi.org/10.18632/oncotarget.10620
Mukherjee S, Debata PR, Hussaini R et al (2017) Unique synergistic formulation of curcumin, epicatechin gallate and resveratrol, tricurin, suppresses HPV E6, eliminates HPV+ cancer cells, and inhibits tumor progression. Oncotarget 8:60904–60916. https://doi.org/10.18632/oncotarget.16648
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4:807–818. https://doi.org/10.1021/mp700113r
Langone P, Debata PR, Dolai S, Curcio GM, Inigo JD, Raja K, Banerjee P (2012) Coupling to a cancer cell-specific antibody potentiates tumoricidal properties of curcumin. Int J Cancer 131:E569–E578. https://doi.org/10.1002/ijc.26479
Langone P, Debata PR, Inigo JDR, Dolai S, Mukherjee S, Halat P, Mastroianni K, Curcio GM, Castellanos MR, Raja K, Banerjee P (2014) Coupling to a glioblastoma-directed antibody potentiates anti-tumor activity of curcumin. Int J Cancer 135:710–719
Mukherjee S, Baidoo J, Fried A, Atwi D, Dolai S, Boockvar J, Symons M, Ruggieri R, Raja K, Banerjee P (2016) Curcumin changes the polarity of tumor-associated microglia and eliminates glioblastoma. Int J Cancer 139:2838–2849. https://doi.org/10.1002/ijc.30398
Zhang X, Tian W, Cai X, Wang X, Dang X, Dang W, Tang H, Cao H, Wang L, Chen T (2013) Hydrazinocurcumin encapsuled nanoparticles “Re-Educate” tumor-associated macrophages and exhibit anti-tumor effects on breast cancer following STAT3 suppression. PLoS One 8:e65896
Debata PR, Castellanos MR, Fata JE, Baggett S, Rajupet S, Szerszen A, Begum S, Mata A, Murty VV, Opitz LM, Banerjee P (2013) A novel curcumin-based vaginal cream Vacurin selectively eliminates apposed himan cervical cancer cells. Gynecol Oncol. 129:145–153
Purkayastha S, Berliner A, Fernando SS, Ranasinghe B, Ray I, Tariq H, Banerjee P (2009) Curcumin blocks brain tumor formation. Brain Res 1266:130–138. https://doi.org/10.1016/j.brainres.2009.01.066
Zhang HG, Kim H, Liu C, Yu S, Wang J, Grizzle WE, Kimberly RP, Barnes S (2007) Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity. Biochim Biophys Acta 1773:1116–1123. https://doi.org/10.1016/j.bbamcr.2007.04.015
Bhattacharyya S, Md Sakib Hossain D, Mohanty S et al. (2010) Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts. Cell Mol Immunol 7:306–315. https://doi.org/10.1038/cmi.2010.11
Chang YF, Chuang HY, Hsu CH, Liu RS, Gambhir SS, Hwang JJ (2012) Immunomodulation of curcumin on adoptive therapy with T cell functional imaging in mice. Cancer Prev Res (Phila.) 5:444–452. https://doi.org/10.1158/1940-6207.capr-11-0308
Luo F, Song X, Zhang Y, Chu Y (2011) Low-dose curcumin leads to the inhibition of tumor growth via enhancing CTL-mediated antitumor immunity. Int Immunopharmacol 11:1234–1240. https://doi.org/10.1016/j.intimp.2011.04.002
Lu Y, Miao L, Wang Y, Xu Z, Zhao Y, Shen Y, Xiang G, Huang L (2016) Curcumin micelles remodel tumor microenvironment and enhance vaccine activity in an advanced melanoma model. Mol Ther 24:364–374. https://doi.org/10.1038/mt.2015.165
Farag SS, Caligiuri MA (2006) Human natural killer cell development and biology. Blood Rev 20:123–137. https://doi.org/10.1016/j.blre.2005.10.001
Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974–1982. https://doi.org/10.1200/JCO.2014.59.4358
Zhang H, Ye Z-l, Yuan Z-G, Luo Z-Q, Jin H-J, Qian Q-J (2016) New strategies for the treatment of solid tumors with CAR-T Cells. Int J Biol Sci 12:718–729. https://doi.org/10.7150/ijbs.14405
Scharton-Kersten T, Afonso L, Wysocka M, Trinchieri G, Scott P (1995) IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol 154:5320–5330
Huang Z, Peng S, Knoff J, Lee SY, Yang B, Wu T-C, Hung C-F (2015) Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model. J Biomed Sci 22:7
Brantley EC, Guo L, Zhang C, Lin Q, Yokoi K, Langley RR, Kruzel E, Maya M, Kim SW, Kim S-J, Fan D, Fidler IJ (2010) Nitric oxide-mediated tumoricidal activity of murine microglial cells. Transl Oncol 3:380–388
Chakravarti N, Myers JN, Aggarwal BB (2006) Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer 119:1268–1275
Ito S, Ansari P, Sakatsume M, Dickensheets H, Vazquez N, Donnelly RP, Larner AC, Finbloom DS (1999) Interleukin-10 inhibits expression of both interferon a– and interferon gamma–induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93:1456–1463
Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR (2008) “Re-educating” tumor-associated macrophages by targeting NF-kB. J Exp Med 205:1261–1268
Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE (2009) Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood 113:3139–3146. https://doi.org/10.1182/blood-2008-12-172825
Ohmori Y, Hamilton TA (2001) Requirement for STAT1 in LPS-induced geneexpression in macrophages. J Leukoc Biol 69:598–604
Vakkila J, Demarco RA, Lotze MT (2008) Coordinate NF-kB and STAT1 activation promotes development of myeloid type 1 dendritic cells. Scand J Immunol 67:260–269
Marotta LLC, Almendro V, Marusyk A et al (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44+ CD24– stem cell–like breast cancer cells in human tumors. J Clin Investig 121:2723–2735. https://doi.org/10.1172/JCI44745
Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163–189. https://doi.org/10.1189/jlb.0603252
Bontkes HJ, Kramer D, Ruizendaal JJ, Meijer CJ, Hooijberg E (2008) Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. Clin Immunol 127:375–384
Hamza T, Barnett JB, Li B (2010) Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci 11:789–806. https://doi.org/10.3390/ijms11030789
Kuge S, Watanabe K, Makino K, Tokuda Y, Mitomi T, Kawamura N, Habu S, Nishimura T (1995) Interleukin-12 augments the generation of autologous tumor-reactive CD8+ cytotoxic T lymphocytes from tumor-infiltrating lymphocytes. Jpn J Cancer Res 86:135–139
Michel T, Hentges F, Zimmer J (2012) Consequences of the crosstalk between monocytes/macrophages and natural killer cells. Front Immunol 3:403. https://doi.org/10.3389/fimmu.2012.00403
Morrison BE, Park SJ, Mooney JM, Mehrad B (2003) Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. J Clin Invest 112:1862–1870. https://doi.org/10.1172/jci18125
Gertsch J, Guttinger M, Heilmann J, Sticher O (2003) Curcumin differentially modulates mRNA profiles in Jurkat T and human peripheral blood mononuclear cells. Bioorg Med Chem 11:1057–1063
Kang TH, Lee JH, Song CK et al (2007) Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res 67:802–811. https://doi.org/10.1158/0008-5472.CAN-06-2638
Bellora F, Castriconi R, Dondero A, Reggiardo G, Moretta L, Mantovani A, Moretta A, Bottino C (2010) The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc Natl Acad Sci USA 107:21659–21664
Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, Hughes TA, Carter CR (2016) Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res 18:10. https://doi.org/10.1186/s13058-015-0669-x
Acknowledgements
Sumit Mukherjee was supported by a teaching assistantship from the College of Staten Island (CUNY).
Funding
This project was supported by Professional Staff Congress (PSC)-CUNY Grants from cycles 45 and 47.
Author information
Authors and Affiliations
Contributions
PB, SM, QP, and LP conceived and planned the experiments. SM, RH, RW, DA, AF, SS, and LP carried out the experiments. All the authors contributed to the interpretation of results. SM and PB took the lead in writing the manuscript. All authors provided critical feedback and helped in shaping the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Probal Banerjee has a pending patent application “Activity Enhancing Curcumin Compositions and Methods of Use”, PCT/US14/67819 pending. The remaining authors declare no conflict of interest.
Ethical approval and ethical standards
All procedures performed in studies involving animals were in accordance with the ethical standards of the Institutional Animal Care Committees (IACUC) at the College of Staten Island (approval # 11 − 008) and The Ohio State University Medical Center (approval # 2009A0172).
Animal source
Adult C57BL/6 female mice (2–6 months old) used for the TC-1 tumor experiments were bred and handled at the College of Staten Island (CUNY) [8]. Athymic nude (NCr) mice were purchased from Charles River Laboratories (Wilmington, MA) for the Head and Neck Squamous Cell Carcinoma (HNSCC) UMSCC47 tumor xenograft model and housed at The Ohio State University animal facility [7]. Both the strains mentioned above were bred and handled in accordance to the consent of respective Institutional Animal Care Committees (IACUC) at the College of Staten Island and The Ohio State University Medical Center. All animal protocols were approved by the respective Institutional Animal Care Committees (IACUC) at the College of Staten Island and The Ohio State University Medical Center.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Mukherjee, S., Hussaini, R., White, R. et al. TriCurin, a synergistic formulation of curcumin, resveratrol, and epicatechin gallate, repolarizes tumor-associated macrophages and triggers an immune response to cause suppression of HPV+ tumors. Cancer Immunol Immunother 67, 761–774 (2018). https://doi.org/10.1007/s00262-018-2130-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-018-2130-3